Collecting and Storing Tissue From Young Patients With Cancer

  • STATUS
    Recruiting
  • participants needed
    213
  • sponsor
    Children's Oncology Group
Updated on 26 January 2021
Investigator
Joseph M. Wiley
Primary Contact
Sinai Hospital of Baltimore (7.8 mi away) Contact
+25 other location
cancer
myeloid leukemia
lymphoid leukemia
lymphoma
leukemia
bone marrow procedure
lymphocytic leukemia
primary cancer
brain tumor
sarcoma
germ cell tumor
cytology specimen collection procedure
germ cell tumors
rhabdoid tumor
acute lymphoblastic leukemia (all)
ewing sarcoma/peripheral primitive neuroectodermal tumor
ewing sarcoma family of tumors

Summary

This laboratory study is collecting and storing tissue, blood, and bone marrow samples from young patients with cancer. Collecting and storing samples of tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.

Description

PRIMARY OBJECTIVES:

I. Establish and bank cell lines and/or xenografts from pediatric patients with cancer.

II. Establish continuous cell lines, under carefully controlled conditions, from pediatric patients with cancer.

III. Establish transplantable xenografts in immunocompromised mice from tumor cells that are difficult to establish as continuous cell lines in vitro.

IV. Create a bank of cell lines and generate sufficient vials of cryopreserved cells for distribution to investigators with approved COG biology protocols. V. Characterize cell lines from childhood cancers with respect to DNA short tandem repeat molecular profile as a "fingerprint" of original cell line identity.

VI. Characterize cell lines for the ability for sustained growth in tissue culture and/or as mouse xenografts.

VII. Characterize cell lines for mycoplasma contamination. VIII. Characterize cell lines for expression of molecular makers that confirm the tumor-type of the cell line and the immortal nature of the cells (telomerase) and the expression of molecular markers that may correlate with drug resistance.

OUTLINE: This is a multicenter study.

Specimens are stratified according to disease (acute lymphoblastic leukemia vs acute myeloid leukemia vs lymphoma vs osteogenic sarcoma vs Ewing family of tumors vs rhabdomyosarcoma vs primitive neuroectodermal tumor vs glioma vs astrocytoma vs rhabdoid tumors vs hepatoblastoma vs retinoblastoma vs Wilms tumor vs germ cell tumors vs other diagnoses).

Leftover tissue from diagnostic procedures and/or surgery is cryopreserved and banked. Blood and/or bone marrow are also collected and banked. Cell lines are established and characterized via reverse-transcriptase polymerase chain reaction and/or flow cytometry for biomarkers and by DNA fingerprinting. Markers to be identified may include the following:

NEUROBLASTOMA: tyrosine hydroxylase, protein gene product (PGP) 9.5, GD2, HLA class I, and HSAN 1.2 antigens

EWING FAMILY OF TUMORS: EWS-FLI1, EWS-ERG, and PGP 9.5

RETINOBLASTOMA: interphotoreceptor retinoid-binding protein

ACUTE LYMPHOBLASTIC LEUKEMIA: immunophenotype

ALVEOLOR RHADOMYOSARCOMA: PAX3-FKHR, PAX7-FKHR, and MyoD1

ALL CELL TYPES: telomerase expression including hTR and hTERTMutations of TP53 gene are detected by flow cytometry and/or immunocytochemistry.

No results of these tests are provided to the patient, the patient's physician, or the patient's medical records.

Details
Condition childhood ALL, Connective and Soft Tissue Neoplasm, Rhabdoid Tumor, Lymphoma, Cancer, leukemia, Central Nervous System Neoplasms, Ewing's sarcoma, Osteosarcoma, Acute myeloid leukemia, Lymphoproliferative Disorder, Lymphoma, Rhabdomyosarcoma, Retinoblastoma, Neuroblastoma, Sarcoma, Germ cell tumor, Non-Hodgkin's Lymphoma, All Solid Tumors, Cancer/Tumors, Solid Tumors, Acute Myelogenous Leukemia (AML), Ewing's Family Tumors, CNS Malignancy, Leukemia (Pediatric), Cancer (Pediatric), Lymphocytic Leukemia, Acute, Sarcoma (Pediatric), Neoplasms, Germ Cell Tumors, Soft Tissue Sarcoma, Lymphoproliferative disorders, acute lymphoblastic leukemia, central nervous system neoplasm, leukemia, acute lymphoblastic, primary cancer, primary malignant neoplasm, cns tumors, cns tumor, cns neoplasm, central nervous system tumors, central nervous system tumor, leukemias, malignancy, cancers, malignancies, malignant tumor, malignant tumors, bone sarcoma, sarcomas, soft tissue sarcomas, malignant central nervous system tumor, central nervous system cancer, lymphomas, acute lymphoid leukaemia, acute lymphocytic leukemia, acute lymphoblastic leukemia (all), acute myelogenous leukemia, anll, acute myeloblastic leukemia, neuroblastomas
Treatment laboratory biomarker analysis, flow cytometry, biologic sample preservation procedure, cytology specimen collection procedure, DNA analysis, reverse transcriptase-polymerase chain reaction
Clinical Study IdentifierNCT00898755
SponsorChildren's Oncology Group
Last Modified on26 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

All malignant tissues from childhood cancers allowed including the following
Brain tumors (all types)
Tissue should be submitted to CNS Committee Resource labs to be forwarded for this study, unless instructed otherwise on the COG web site
Ewing family of tumors
Rhabdomyosarcomas
Other soft tissue sarcomas
Osteogenic sarcomas
Rhabdoid tumors
Neuroblastomas
Viable material for cell culture for neuroblastoma is collected via COG-ANBL00B1 and should not be submitted via this study unless the patient cannot be enrolled on COG-ANBL00B1
Retinoblastomas
Anaplastic Wilms tumor
Germ cell tumors
Leukemias/lymphomas
Acute myeloid leukemia (AML)
Blood samples and bone marrow samples from patients at second relapse and beyond may be submitted for this study
Bone marrow samples at diagnosis or first relapse must be submitted to an AML resource lab and will be forwarded for this study at the discretion of the AML Committee
Acute lymphoblastic leukemia (ALL)
Blood samples may be submitted directly to this study
Bone marrow samples must be submitted to an ALL resource lab and will be forwarded for this study at the discretion of the ALL Committee
Enrolled on a COG therapeutic, biology, or tissue banking protocol that allows collection of tissue for research and submission to a COG-designated resource laboratory
Participation in this protocol is not permitted until after tissue requirements for any active COG disease-specific therapeutic, biology, or banking protocols have been satisfied
Material may only be submitted for this protocol if tissue is available in excess of that required for satisfying active disease-specific therapeutic and biological protocols
Patients with diagnosis pending are eligible
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note